Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
143.56 USD | -0.41% | +4.37% | -10.82% |
04:47pm | AbbVie, BigHat Biosciences Partner to Develop Therapeutic Antibodies Using AI | MT |
03:21pm | Johnson & Johnson forecasts as much as 6% sales growth in 2024 | RE |
Evolution of the average Target Price on AbbVie Inc.
Price target over the last 5 years
History : Analyst Recommendations
b65503.JVlkeKbhAtpEFC8bon4xYQSpVlQhI4NM2Dkoe5ZREZ4.cxUrCOqnXa13chxo20YGF1XrORlRdrB-6lVaOtAWd_FSLAsN8dNWrnxuSA~68b615f978b163d25178051632649b66
More recommendations
Analysts' Consensus
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
144.15USD
Average target price
167.35USD
Spread / Average Target
+16.09%
High Price Target
201USD
Spread / Highest target
+39.44%
Low Price Target
126USD
Spread / Lowest Target
-12.59%
Consensus detail
Consensus revision (last 18 months)
Analysts covering AbbVie Inc.
Raymond James | |
Deutsche Bank Securities | |
Morgan Stanley | |
Barclays | |
UBS | |
William Blair & Co. | |
HSBC | |
Guggenheim | |
Wells Fargo Securities | |
Argus | |
Wolfe Research | |
Piper Sandler | |
Atlantic Equities | |
SVB Securities LLC | |
BMO Capital | |
Truist Securities | |
Credit Suisse | |
Societe Generale | |
Goldman Sachs | |
Berenberg Bank | |
JPMorgan Chase | |
Cowen | |
Redburn | |
Mizuho Securities | |
SVB Leerink | |
Daiwa Securities | |
RBC Capital Markets |
Trading Rating :
Investor Rating :
ESG Refinitiv :
C+
EPS Revisions
- Stock
- Equities
- Stock AbbVie Inc. - Nyse
- Consensus AbbVie Inc.